Crizalk (Crizotinib)

Crizalk contains Crizotinib. This targeted cancer treatment is used to treat certain non-small lung cancers (NSCLCs) with ALK mutations or ROS1 gene mutations. This new therapy works by blocking the signals that promote tumor cell growth. It offers hope of improved outcomes.

What is Crizalk?

Crizalk is a TKI containing Crizotinib. This TKI interferes with certain enzymes, such as ALK and ROS1, that are involved in NSCLC development and progression. Crizalk, by blocking these enzymes and preventing tumour growth, is a valuable option for those with ALK-positive or ROS1-positive lung cancers.

Key Features

• Active Ingredient: Crizotinib
• Drug Class: Tyrosine kinase inhibitor (TKI)
• Indication: ALK-positive and ROS1-positive non-small cell lung cancer
• Form: Oral capsules
• Dosage: Oncologists prescribe chemotherapy
• Prescription: Required in Australia

How Does Crizalk Work?

Crizalk blocks and targets the ALK and ROS1 proteins, both of which are drivers in cancer cell proliferation and survival. Crizalk inhibits these kinases and disrupts the signalling pathways of cancer cells, resulting in reduced tumour growth or even tumour shrinkage.

Who Should Use Crizalk?

• Patients with metastatic or advanced non-small cell lung carcinoma who have confirmed ALK and ROS1 rearrangements.
• Patients who need targeted treatment after undergoing other therapies.
• Regular monitoring of patients under the supervision of an oncologist specialist.

Crizalk (Crizotinib) vs Other Targeted Lung Cancer Therapies

How to Take Crizalk

• Crizalk should be taken exactly as directed by your oncologist. This is usually twice daily, with or without eating.
• Do not chew or crush capsules. Swallow them whole, with water.
• To maintain consistent levels of blood, adhere strictly to the dosing schedule.
• Follow-up visits are important to monitor side effects and the treatment’s response.
• Any unusual side effects or symptoms should be reported immediately.

Possible Side Effects

• Vision problems (blurred vision, flashes of light)
• Nausea and vomiting
• Diarrhea or constipation
• Fatigue and swelling
• Liver enzyme elevations
• Shortness of breath or cough

If you have severe side effects, such as severe chest pain or breathing problems, or liver symptoms (jaundice and dark urine), contact your doctor immediately.

Precautions and Warnings

• The treatment requires regular blood tests to monitor liver function.
• Crizalk may be affected by grapefruit and grapefruit juice.
• Tell your doctor all of the medications you are taking and any supplements that you take to avoid interactions.
• During treatment, pregnancy and breastfeeding are contraindicated.
• If you feel dizzy or have vision problems, do not drive heavy equipment.

10 Unique FAQs — What, How, Why

1. What types of cancer does Crizalk treat?

Non-small-cell lung cancer is primarily ALK or ROS1-positive.

2. How does Crizalk target cancer cells?

Inhibiting ALK and ROS1 enzymes that are involved in the growth of cancer.

3. Why is genetic testing necessary before starting Crizalk?

It is important to confirm ALK mutations or ROS1 mutations in order to receive effective treatment.

4. How long is Crizalk treatment usually continued?

If the disease progresses or if unacceptable side effects are experienced, then it is time to seek medical attention.

5. What should I do if I miss a dose?

Do not take a second dose if you haven’t taken it yet.

6. Can Crizalk cause vision problems?

Yes, some patients do report visual impairment or blurred vision.

7. Are there dietary restrictions during Crizalk therapy?

Other than that, there are no restrictions.

8. What monitoring is required during treatment?

Blood tests, ECGs, imaging, and liver functions.

9. Can Crizalk be combined with other cancer treatments?

Inform your oncologist of all treatment options.

10. Is Crizalk suitable for all lung cancer patients?

No, Only those who have confirmed ALK gene rearrangements or ROS1 genes.

Final Thoughts

Crizalk (Crizotinib) is a breakthrough in the treatment of lung cancer for Australians with ALK-positive or ROS1-positive NSCLC. Under expert guidance, the drug can provide targeted tumor control with improved outcomes.